Plaque Psoriasis Market (U.S., EU5, Japan) to Reach USD 46.82 Billion by 2030

Sub-Headline: The Plaque Psoriasis Market across the 6/8 major pharmaceutical markets (U.S., Germany, France, Italy, Spain, U.K., and Japan) is projected to grow from USD 32.10 billion in 2023 to USD 46.82 billion by 2030, at a CAGR of 5.5%, driven by rising prevalence, biologic expansion, and advanced immunomodulators.

Introduction
The Plaque Psoriasis Market in the 6/8 major markets continues to demonstrate strong growth as demand for targeted biologics, interleukin inhibitors, JAK inhibitors, and next-generation systemic therapies increases. Plaque psoriasis, the most common form of psoriasis, affects millions across the U.S., Europe, and Japan, creating significant demand for advanced treatments that offer long-term remission, lower relapse rates, and improved quality of life.
The market is rapidly transforming due to the introduction of IL-17, IL-23, TNF-α inhibitors, biosimilars, oral small molecules, and emerging therapies in Phase II/III pipelines.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/73643

Key Takeaways
• Market Size (2023): USD 32.10 Billion
• Expected Market Size (2030): USD 46.82 Billion
• CAGR (2024-2030): 5.5%
• Growth driven by increased biologic uptake and rising diagnosis rates.
• Key companies include AbbVie, Novartis, Amgen, Eli Lilly, Pfizer, Johnson & Johnson (Janssen), UCB Pharma, Bristol-Myers Squibb, Leo Pharma, and Boehringer Ingelheim.
• High adoption of IL-23 and IL-17 inhibitors due to superior skin clearance profiles.

Market Story
Plaque psoriasis affects over 22-24 million patients across the U.S., EU5, and Japan combined. The rise in prescription volumes for biologics and advanced systemic therapies continues to drive strong revenue growth. Treatment innovation is accelerating due to:

1. Expansion of IL-23 & IL-17 Inhibitors
IL-23 drugs such as Guselkumab, Risankizumab, and Tildrakizumab offer longer remission periods, while IL-17 inhibitors like Secukinumab and Ixekizumab are delivering rapid response rates.

2. Biosimilar Uptake
Price pressures in EU markets and expected U.S. biosimilar launches are increasing patient access:
• TNF-α biosimilars
• Upcoming IL-inhibitor biosimilars
• Lower-cost systemic alternatives

3. Increasing Use of Oral Therapies
Small molecules such as:
• Apremilast (PDE4 inhibitor)
• Deucravacitinib (TYK2 inhibitor)
are gaining popularity for moderate plaque psoriasis where biologics are not preferred.

4. Emerging Curative Research
New modalities under development include:
• RNA-based therapies
• Microbiome-targeting drugs
• Advanced topical immunomodulators
• Long-acting injectable formulations
The push toward durable remission is shaping future pipelines.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/73643/plaque-psoriasis-in-68-market

Market Segments
By Drug Class
• IL-23 Inhibitors
• IL-17 Inhibitors
• TNF-α Inhibitors
• PDE4 Inhibitors
• TYK2 & JAK Inhibitors
• Topical Corticosteroids & Calcineurin Inhibitors
• Biosimilars

By Route of Administration
• Injectable Biologics
• Oral Therapies
• Topical Agents

By Distribution Channel
• Hospital Pharmacies
• Retail & Specialty Pharmacies
• Online Pharmacies

By Geography (6/8 Markets)
• United States (largest market, >55% share)
• Germany, France, U.K., Italy, Spain (EU5)
• Japan

Recent Developments
• AbbVie strengthened Humira's successor lineup with Skyrizi (IL-23), achieving record market share.
• Novartis expanded real-world evidence data supporting Cosentyx for long-term remission.
• Lilly reported strong uptake for Taltz in moderate-severe plaque psoriasis.
• Janssen advanced clinical trials for next-generation IL-23 assets.
• UCB expanded global access to Bimzelx (IL-17A/F dual inhibitor).
• Pfizer and BMS explored new TYK2/JAK inhibitors targeting psoriasis pathways.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73643

Expert Quote
"The plaque psoriasis landscape is evolving rapidly, with IL-23 and TYK2 inhibitors setting new standards for durable skin clearance. As biologics expand globally, patient access, pricing, and biosimilar competition will shape the next phase of market growth."
-Irfan Tamboli, Business Development Executive, Exactitude Consultancy

Market Drivers
• Rising prevalence and improved diagnosis rates
• Strong clinical performance of IL-23/IL-17 biologics
• Biosimilar expansion reducing treatment costs
• Growing preference for oral targeted therapies
• Increasing patient access programs in EU & Japan
• High R&D investment in immunomodulation and dermatology

Forecast Outlook
The market will exceed USD 46.82 billion by 2030, driven by:
• Higher biologic penetration
• Increased availability of biosimilars
• Strong commercial performance in the U.S.
• Growth in Japan's dermatology therapeutics segment

Regional Highlights
• U.S. dominates with the highest biologic usage and pricing.
• EU5 shows rising biosimilar utilization and cost-optimization policies.
• Japan is expanding systemic therapy adoption, especially IL-23 agents.

Government & Regulatory Initiatives
• FDA approval pathways for biologics & biosimilars
• EMA's accelerated approvals for dermatology innovations
• Japan PMDA initiatives supporting immunology drug development
• Government reimbursement expansions improving biologic accessibility
• National psoriasis management guidelines emphasizing systemic therapy

Conclusion
The Plaque Psoriasis Market across major global markets is entering a new era, driven by biologic dominance, next-generation immunotherapies, and strong biosimilar expansion. Companies focusing on IL-23, TYK2, and combination immunomodulators are expected to lead the therapeutic evolution through 2030.

This report is also available in the following languages : Japanese (68マーケットのプラーク乾癬), Korean (68마켓의 플라크 건선), Chinese (68 市场中的斑块状银屑病), French (Psoriasis en plaques sur 68 marchés), German (Plaque-Psoriasis in 68 Markt), and Italian (Psoriasi a placche nel mercato 68), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/73643

Our More Reports:

Electronic Skin Market
https://exactitudeconsultancy.com/reports/74640/electronic-skin-market

Managed Services Market
https://exactitudeconsultancy.com/reports/74641/managed-services-market

Military Cloud Computing Market
https://exactitudeconsultancy.com/reports/74642/military-cloud-computing-market

Smart Clothing Market
https://exactitudeconsultancy.com/reports/74643/smart-clothing-market

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

This release was published on openPR.